Bolt Biotherapeutics, Inc.BOLTEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| NOS. of Above Persons | 9.60% | 3.7M | — | 2024-02-14 |
| Nan Fung Group Holdings Limited | 8.10% | 3.1M | — | 2024-02-12 |
| Vivo Capital Fund VIII, L.P. | 4.80% | 1.8M | — | 2024-02-13 |
| Citadel Advisors LLC | 0.00% | 38.3M | ▼ -6.20pp | 2024-11-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.